{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:52:16Z","timestamp":1790970736981,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41591-023-02385-6","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T12:03:06Z","timestamp":1688990586000},"page":"1718-1727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495\/KeyImPaCT trial interim results"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-3159","authenticated-orcid":false,"given":"Martin","family":"Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Sen","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Gubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"Daniel Shao Weng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-3166","authenticated-orcid":false,"given":"Joanne W. Y.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8801","authenticated-orcid":false,"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Landers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Palcza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-0339","authenticated-orcid":false,"given":"Razvan","family":"Cristescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3523","authenticated-orcid":false,"given":"Alexandra","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-5847","authenticated-orcid":false,"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"2385_CR1","unstructured":"Bristol Myers Squibb. OPDIVO (nivolumab) injection, for intravenous use (US prescribing information). https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf (2022)."},{"key":"2385_CR2","unstructured":"Genentech. TECENTRIQ (atezolizumab) injection, for intravenous use (US prescribing information). https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf (2022)."},{"key":"2385_CR3","unstructured":"Merck. KEYTRUDA (pembrolizumab) injection, for intravenous use. (US prescribing information). https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf (2023)."},{"key":"2385_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"2385_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2385_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2385_CR7","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"2385_CR8","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"2385_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2385_CR10","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","volume":"28","author":"R Cristescu","year":"2022","unstructured":"Cristescu, R. et al. Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types. Clin. Cancer Res. 28, 1680\u20131689 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2385_CR11","doi-asserted-by":"publisher","first-page":"LBA79","DOI":"10.1093\/annonc\/mdz394.077","volume":"30","author":"RS Herbst","year":"2019","unstructured":"Herbst, R. S. et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Ann. Oncol. 30, LBA79 (2019).","journal-title":"Ann. Oncol."},{"key":"2385_CR12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s40425-019-0643-8","volume":"7","author":"D Aurora-Garg","year":"2019","unstructured":"Aurora-Garg, D. et al. Large-scale evaluation of concordance of genomic scores in whole exome sequencing and foundation medicine comprehensive genomic platform across cancer types. J. Immunother. Cancer 7, 172 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2385_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30380-x","volume":"13","author":"LA Keefer","year":"2022","unstructured":"Keefer, L. A. et al. Automated next-generation profiling of genomic alterations in human cancers. Nat. Commun. 13, 2830 (2022).","journal-title":"Nat. Commun."},{"key":"2385_CR14","doi-asserted-by":"publisher","first-page":"LBA80","DOI":"10.1093\/annonc\/mdz394.078","volume":"30","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann. Oncol. 30, LBA80 (2019).","journal-title":"Ann. Oncol."},{"key":"2385_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.annonc.2020.11.020","volume":"32","author":"R Perets","year":"2020","unstructured":"Perets, R. et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann. Oncol. 32, 395\u2013403 (2020).","journal-title":"Ann. Oncol."},{"key":"2385_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor, M. H. et al. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 38, 1154\u20131163 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2385_CR17","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2021.39.15_suppl.3584","volume":"39","author":"E Garralda","year":"2021","unstructured":"Garralda, E. et al. A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. J. Clin. Oncol. 39, 3584\u20133584 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2385_CR18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2385_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2385_CR20","doi-asserted-by":"publisher","first-page":"LB-261","DOI":"10.1158\/1538-7445.AM2020-LB-261","volume":"80","author":"R Cristescu","year":"2020","unstructured":"Cristescu, R. et al. Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy. Cancer Res. 80, LB-261 (2020).","journal-title":"Cancer Res."},{"key":"2385_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446\u2013454 (2018).","journal-title":"Nature"},{"key":"2385_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang, M., Herbst, R. S. & Boshoff, C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat. Med. 27, 1345\u20131356 (2021).","journal-title":"Nat. Med."},{"key":"2385_CR23","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.esmoop.2022.100639","volume":"6","author":"E Garralda","year":"2022","unstructured":"Garralda, E. et al. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open 6, 100639 (2022).","journal-title":"ESMO Open"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02385-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02385-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02385-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T09:19:58Z","timestamp":1689671998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02385-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02385-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.G. reports a speaker role with Guardant Health; a consultant role with Cellularity; and stocks\/shares with COTA. M.D.H. reports grants from Bristol Myers Squibb; personal fees from Achilles, Adagene, Adicet, Arcus, AstraZeneca, Blueprint, Bristol Myers Squibb, DaVolterra, Eli Lilly, Genentech\/Roche, Genzyme\/Sanofi, Janssen, Immunai, Instil Bio, Mana Therapeutics, Merck, Mirati, Natera, Pact Pharma, Shattuck Labs and Regeneron; and equity options from Factorial, Immunai, Shattuck Labs, Arcus and Avail Bio. A patent filed by Memorial Sloan Kettering related to the use of tumor mutational burden to predict response to immunotherapy (PCT\/US2015\/062208) is pending and licensed by Personal Genome Diagnostics. Subsequent to the completion of this work, M.D.H. began as an employee (and equity holder) at AstraZeneca. M.A.G. reports funding to institution from Amgen, Celgene, Johnson & Johnson, Merck, Novartis, Oncomed and Trizill and personal financial interests in AstraZeneca, Bristol Myers Squibb, Genentech\/Roche, Guardant Health, iTeos, Surface and Genzyme\/Sanofi. C.A. reports consulting or advisory roles with Genentech, Eli Lilly, Celgene, Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo, Regeneron, Sanofi, Eisai, Beigene, Turning Point, Pfizer, Janssen and Boehringer Ingelheim and research funding to institution from Genentech, Roche, Incyte, Macrogenics, Merck Sharp & Dohme and AstraZeneca\/MedImmune. D.S.W.T. reports consultancy with Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, DKSH, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Takeda and grant\/research support from ACM Biolabs, Amgen, AstraZeneca and Pfizer. E.F. reports roles on advisory boards for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Merck Serono, Novartis, Peptomyc, Pfizer, Sanofi and Takeda; speaker roles with Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen, Medscape, Merck Sharp & Dohme, Peervoice, Pfizer, Medical Trends, Merck Serono, Sanofi, Takeda and TouchOncology; research funding from Merck KGaA and Fundacion Merck Salud; and independent fees from Grifols. J.C.-H.Y. reports personal fees and other from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceuticals, Pfizer, Roche\/Genentech, Takeda Oncology, Yuhan Pharmaceuticals, Johnson & Johnson, Puma Technology, Gilead and GlaxoSmithKline. E.B.G. reports consultant and\/or advisor roles for ABL-Bio, AstraZeneca, AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dracen Pharmaceuticals, EMD Serono, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Natera, Novartis, Personalis, Regeneron, Sanofi, Shionogi and Xilio and grand\/research support from ABL-Bio, AstraZeneca, Bristol Myers Squibb, Dynavax Technologies, Eli Lilly, EMD Serono, Genentech, Iovance Biotherapeutics, Merck, Mirati Therapeutics, Neon and Novartis. A.B., J.K., H.M., J.P., R.C. and J.Y. report employment and stock ownership at Merck Sharp & Dohme. H.M. and A.S. were previously employed by and report stock ownership at Merck Sharp & Dohme. L.F. has received research support from Roche\/Genentech, AbbVie, Bavarian Nordic, Bristol Myers Squibb, Dendreon, Janssen, Merck and Partner Therapeutics and served on the scientific advisory boards of Actym, Alector, AstraZeneca, Atreca, Bioalta, Bolt, Bristol Myers Squibb, Daiichi Sankyo, Immunogenesis, Innovent, Merck, Merck KGaA, Nutcracker, RAPT, Scribe, Senti, Soteria, Sutro and Roche\/Genentech. R.S.H. reports consulting roles with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Eli Lilly, EMD Serono, Genentech\/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics; advisory board roles with AstraZeneca, Bolt Biotherapeutics, Cybrexa Therapeutics, EMD Serono, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Neon Therapeutics, Novartis and STCube Pharmaceuticals; research support from AstraZeneca, Eli Lilly, Genentech\/Roche and Merck; and non-executive board membership for Junshi Pharmaceuticals and Immunocore. W.-S.L., J.W.Y.C., J.-S.L., G.F., M.-J.A., A.L. and G.A.L. have no competing interests to report. Funding for this research was provided by Merck Sharp & Dohme. The funder participated in study design, data analysis and interpretation and manuscript writing and maintained the study database. All authors had full access to the data and had final responsibility for the decision to submit the manuscript for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}